The medicines decisions made at the NENC Clinical Effectiveness and Governance (CEG) Subcommittee February 2025 meeting can now be found at: https://ntag.nhs.uk/meetings/decision-summaries/
This includes the recommendations made by NTAG at its January 2025 meeting and NICE Technology appraisals from the 1st October 2024 to 30th November 2024.
The following new guidelines were approved and can be found at:
- NENC Bupropion for resistant depression – Information for Primary Care – https://ntag.nhs.uk/guidelines/
- NENC COPD Guideline – https://ntag.nhs.uk/guidelines/
- NENC Guidelines for the recognition and management of non-IgE cow’s milk protein allergy (CMA) in infants – https://ntag.nhs.uk/guidelines/
- NENC Prescribing Guideline for Management of Stoma (Colostomy, Ileostomy and Urostomy) in adult patients – https://ntag.nhs.uk/guidelines/
The following guidelines have also had some minor amendments/updates:
- NENC Guidelines: Self-Monitoring of Blood Glucose and Ketones in Diabetes – updated version https://ntag.nhs.uk/guidelines/
- North East Guideline For Use Of Sodium Glucose Co transporter 2 Inhibitors (SGLT2i) – updated version https://ntag.nhs.uk/guidelines/
The following share care guidelines were also approved and will be published on the NTAG website shortly:
- NENC Hydroxychloroquine SCG – technical update
- NENC Lithium SCG for adult patients within mental health services
- NENC Sulfasalazine, Leflunomide and Mycophenolate in adults (non-transplant indications) SCGs